Parkinson Disease clinical trials

Explore recruiting parkinson disease clinical trials.

Recruiting parkinson disease studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Parkinson Disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Exploratory study of the expression of the serotonergic 5-HT4 receptor in Parkinson's disease

France

Phase II and Phase III (Integrated) EU CTIS Study details

Evaluation of long-term safety in parkinsonian patients with intracerebroventricular administration of A-dopamine (anaerobic dopamine) - (DIVE-Follow up)

France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Bioequivalence study 1 to compare pharmacokinetics of Parkinson´s disease drugs in healthy volunteers

Czechia

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of CVN424 in Parkinson’s Disease Patients with Motor Complications

Czechia, Poland, France, Spain, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A study to find out how healthy people tolerate a new drug called S221237.

France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

INITIATE-LECIG: Intestinal levodopa + entacapone therapy (Lecigon®) to counteract dopaminergic desensitization and neuropsychiatric complications in Parkinson’s disease

Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Parkinson Disease trials by city

Parkinson Disease in Toronto Parkinson Disease in Vancouver Parkinson Disease in Montreal Parkinson Disease in Calgary Parkinson Disease in Edmonton Parkinson Disease in Ottawa Parkinson Disease in Winnipeg Parkinson Disease in Quebec City Parkinson Disease in Hamilton Parkinson Disease in Kitchener Parkinson Disease in London Parkinson Disease in Halifax Parkinson Disease in New York Parkinson Disease in Los Angeles Parkinson Disease in Chicago Parkinson Disease in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease